# Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

> **NCT02273960** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 46 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **DRUG:** BMS-986004 75 mg IV
- **DRUG:** BMS-986004 225 mg IV
- **DRUG:** BMS-986004 675 mg IV
- **DRUG:** BMS-986004 1500 mg IV

## Key facts

- **NCT ID:** NCT02273960
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-17
- **Primary completion:** 2018-01-22
- **Final completion:** 2018-01-22
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273960, "Study to Evaluate Safety and Efficacy in Adult Subjects With ITP". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02273960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*